Coagulation Market Worth $10.85 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
16. Oktober 2023 08:13 ET
|
The Insight Partners
Pune, India, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Coagulation or clotting is the process by which blood turns from a liquid into a gel and forms a blood clot. This potentially leads to hemostasis,...
Hemophilia A Market to Exhibit Growth at a Remarkable CAGR During the Study Period (2019-2032) | DelveInsight
09. Oktober 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Hemophilia A Market to Exhibit Growth at a Remarkable CAGR During the Study Period (2019-2032) | DelveInsight The current therapeutic landscape...
Freeline to Present at the Stifel Healthcare Conference
09. November 2022 07:00 ET
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...
Global Hemophilia Gene Therapy Market to Surpass US$ 2,197.9 Million by 2030, Says Coherent Market Insights (CMI)
24. August 2022 08:40 ET
|
CMI
Seattle, Aug. 24, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global hemophilia gene therapy market is estimated to be valued at US$ 330.9 million in 2022 and is expected to...
Global Hemophilia A Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight
29. März 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, March 29, 2022 (GLOBE NEWSWIRE) -- Global Hemophilia A Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight Hemophilia A Pipeline constitutes 40+...
Hemophilia Treatment Market worth $16 Billion by 2028, Says Global Market Insights Inc.
01. März 2022 05:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, March 01, 2022 (GLOBE NEWSWIRE) -- Hemophilia treatment market revenue is projected to reach USD 16 billion by 2028, according to a new research report by Global Market...
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
04. Februar 2020 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
06. November 2019 09:16 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
06. Juli 2019 07:00 ET
|
uniQure Inc.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All...
uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
21. Juni 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...